Drug intelligence / Profile preview

doxorubicin + vinblastine

Development stage: Unknown
Lead developer: Farmitalia
Modality: Small Molecules
Administration: Intravenous

Overview

Doxorubicin + vinblastine is a chemotherapy combination used in various regimens for cancer treatment. Doxorubicin (also called Adriamycin) is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, while vinblastine is a vinca alkaloid that binds to tubulin and inhibits microtubule assembly. Together, these drugs destroy rapidly dividing cells, such as cancer cells. This combination is commonly used as part of multi-drug regimens including ABVD (with bleomycin and dacarbazine) for Hodgkin lymphoma and M-VAC (with methotrexate and cisplatin) for urothelial carcinoma.

Other names: DOX/VBL

Targets

TUBB (Tubulin (alpha and beta subunits))ABCB1 (P-glycoprotein)DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on doxorubicin + vinblastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + vinblastine.

Explore the full profile